| Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up
|
Postprandial blood glucose predicts cardiovascular events and all cause mortality in type 2 diabetes in a 14 year follow up Cavalot F, Pagliarino A, Valle M, et al. Diabetes Care. 2011 34(10) 2237 2243. This overview was created under the |
|
|
| Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors
|
Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors Varanasi A, Patel P, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P. Endocr Pract. 2011 Aug 19 1 13. Epub ahead of print. Varanasi and |
|
|
| Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial
|
Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes. Unick JL, Beavers D, Jakicic JM, et al for the Look AHEAD Research Group. Diabetes Care. 2011 34(10) 2152 2157. This overview was created under the auspices |
|
|
| Proportion of patients at HbA1c target greater than 7% with eight classes of antidiabetic drugs in type 2 diabetes
|
| Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients. Diabetes Obes Metab. 2011 Sep 29. doi: 10.1111/j.1463-1326.2011.01512.x. [Epub ahead of print] |
|
|
| Glucagon-like peptide analogues for type 2 diabetes mellitus
|
| Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. CochraneDatabase Syst Rev. 2011 Oct 5;(10):CD006423. |
|
|
| Health-related quality of life in subjects with and without Type 2 diabetes: pooled analysis of five population-based surveys in Germany
|
| Schunk M, Reitmeir P, Schipf S, Völzke H, Meisinger C, Thorand B, Kluttig A, Greiser KH, Berger K, Müller G, Ellert U, Neuhauser H, Tamayo T, Rathmann W, Holle R. Health-related quality of life in subjects with and without Type 2 diabetes: pooled analysis of five population-based surveys in Germany. Diabet Med. 2011 Oct 6. doi: 10.1111/j.1464-5491.2011.03465.x. [Epub ahead of print] |
|
|
| Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial
|
| Sperl-Hillen J, Beaton S, Fernandes O, Von Worley A, Vazquez-Benitez G, Parker E, Hanson A, Lavin-Tompkins J, Glasrud P, Davis H, Adams K, Parsons W, Spain CV. Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial. Arch Intern Med. 2011 Oct 10. [Epub ahead of print] |
|
|
| Supervised exercise training counterbalances the adverse effects of insulin therapy in overweight/obese subjects with type 2 diabetes
|
| Balducci S, Zanuso S, Cardelli P, Salerno G, Fallucca S, Nicolucci A, Pugliese G; for the Italian Diabetes Exercise Study (IDES) Investigators. Supervised exercise training counterbalances the adverse effects of insulin therapy in overweight/obese subjects with type 2 diabetes. Diabetes Care. 2011 Oct 19. [Epub ahead of print] |
|
|
| Dietary glycemic index and glycemic load in relation to the risk of type 2 diabetes: a meta-analysis of prospective cohort studies
|
| Dong JY, Zhang L, Zhang YH, Qin LQ. Dietary glycemic index and glycemic load in relation to the risk of type 2 diabetes: a meta-analysis of prospective cohort studies. Br J Nutr. 2011 Sep 29:1-6. [Epub ahead of print] |
|
|
| Risk factors for hypoglycemia-related hospitalization in patients with type 2 diabetes: a nested case-control study
|
| Quilliam BJ, Simeone JC, Ozbay AB. Risk factors for hypoglycemia-related hospitalization in patients with type 2 diabetes: a nested case-control study. Clin Ther. 2011 Oct 20. [Epub ahead of print] |
|
|
| The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers
|
| Samaropoulos XF, Light L, Ambrosius WT, Marcovina SM, Probstfield J, Jr DC. The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Res Clin Pract. 2011 Oct 21. [Epub ahead of print] |
|
|
| Patients' education, and its impact on care outcomes, resource consumption and working conditions: Data from the IDMPS
|
| Gagliardino JJ, Aschner P, Baik SH, Chan J, Chantelot JM, Ilkova H, Ramachandran A; IDMPS investigators. Patients' education, and its impact on care outcomes, resource consumption and working conditions: Data from the International Diabetes Management Practices Study (IDMPS). Diabetes Metab. 2011 Oct 21. [Epub ahead of print] |
|
|
| Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes
|
| Cohen LB, Taviera TH, Khatana SA, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011 Oct 21. [Epub ahead of print] |
|
|
| Metabolic outcomes 1 year after gastric bypass surgery in obese people with type 2 diabetes
|
| Demssie YN, Jawaheer J, Farook S, New JP, Syed AA. Metabolic outcomes 1 year after gastric bypass surgery in obese people with type 2 diabetes. Med Princ Pract. 2011 Oct 20. [Epub ahead of print] |
|
|
| Evaluating the long-term cost-effectiveness of liraglutide vs exenatide BID in patients w/ type 2 diabetes who fail to improve w/ oral antidiabetic agents
|
| Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011 Oct 19. [Epub ahead of print] |
|
|
| Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
|
| Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes. 2011 Oct 17. [Epub ahead of print] |
|
|
| Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
|
| Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med. 2011 Aug 29. doi: 10.1111/j.1464-5491.2011.03429.x. [Epub ahead of print] |
|
|
| National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980
|
| Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980. Lancet. 2011;378(9785):31-40. |
|
|
| Management of type 2 diabetes: new and future developments in treatment
|
| Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786):182-97. |
|
|
| HbA1c 5.7-6.4% & impaired fasting plasma glucose for diagnosis of prediabetes & risk of progression to diabetes in Japan (TOPICS 3)
|
| Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, Kodama S, Hsieh SD, Mori Y, Shimano H, Yamada N, Kosaka K, Sone H. HbA1c 5.7-6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet. 2011;378(9786):147-55. |
|
|
| Insulin detemir versus insulin glargine for type 2 diabetes mellitus
|
| Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011 Jul 6;7:CD006383. |
|
|
| Review of approved pioglitazone combinations for type 2 diabetes
|
| Forst T, Hanefeld M, Pfützner A. Review of approved pioglitazone combinations for type 2 diabetes. Expert Opin Pharmacother. 2011;12(10):1571-84. |
|
|
| Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes
|
| Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgrad Med. 2011;123(4):63-70. |
|
|
| Clinical Outcomes Using Long-Term Combination Therapy With Insulin Glargine and Exenatide In Patients With Type 2 Diabetes
|
| Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical Outcomes Using Long-Term Combination Therapy With Insulin Glargine and Exenatide In Patients With Type 2 Diabetes. Endocr Pract. 2011 Jul 8:1-28. [Epub ahead of print] |
|
|
| Efficacy & Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared w/ Exenatide Twice Daily & Sitagliptin in Type 2 Diabetes Mellitus
|
| Pinelli NR, Hurren KM. Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis (July/August) Ann Pharmacother. 2011 Jul 5. [Epub ahead of print] |
|
|